CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Rasagiline +1 moredrug
Likely dose
Rasagiline 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01168596
NCT01168596Phase 4Completed
CompareCT.gov

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial)

University of Florida·interventional·Posted Jul 23, 2010·Updated Jan 10, 2014

In Brief

A Phase 4 clinical trial evaluating Rasagiline and Placebo for Parkinson's Disease. Completed, enrolled 30 participants across 3 sites.

Detailed Summary

The purpose of the research study is to determine if rasagiline is an effective treatment for fatigue in patients with Parkinson's disease (PD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 23, 2010
Enrollment StartDec 1, 2009
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 15.9 years ago

Interventions

Rasagilinedrug

Comparison of Rasagiline versus placebo. Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks.

Placebodrug

Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.